Abstract | PURPOSE: METHODS: We reviewed 114 patients who underwent primary whole-gland prostate cryoablation for localized prostate cancer from October 2008 to March 2013. The perioperative parameters included age >70 years, initial prostate-specific antigen (PSA), preoperative prostate volume, Gleason score, T stage, D'Amico risk group, postoperative PSA nadir, time to PSA nadir, and PSA biochemical recurrence, defined by Phoenix definition (nadir plus 2 ng/mL). Receiver operating characteristic (ROC) analysis was used for the best cutoff value of PSA nadir for PSA biochemical recurrence. The parameters were analyzed in binary logistic regression and Kaplan-Meier analysis for PSA biochemical recurrence. RESULTS: A total of 31.6 % (N = 36) patients had PSA biochemical recurrence during the median follow-up of 34.87 ± 16.49 months. ROC analysis revealed that the best cutoff value for biochemical recurrence prediction was when the PSA nadir = 0.3 ng/mL. On multivariate analysis and Kaplan-Meier analysis, the D'Amico high-risk group [hazard ratio (HR) 6.552; p = 0.014], PSA nadir >0.3 ng/mL (HR 34.062; p < 0.001), and time to PSA nadir <3 months (HR 4.144; p = 0.021) were statistically significant for PSA biochemical recurrence. CONCLUSIONS: The D'Amico high-risk group, postoperative PSA nadir >0.3 ng/mL, and time to PSA nadir <3 months predict biochemical recurrence in primary whole-gland prostate cryoablation.
|
Authors | Yi Yang Liu, Po Hui Chiang, Yao Chi Chuang, Wei Ching Lee, Yuan Tso Cheng, Hung Jen Wang |
Journal | Annals of surgical oncology
(Ann Surg Oncol)
Vol. 22
Issue 5
Pg. 1612-7
(May 2015)
ISSN: 1534-4681 [Electronic] United States |
PMID | 25287436
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- Prostate-Specific Antigen
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biomarkers, Tumor
(blood)
- Combined Modality Therapy
- Cryosurgery
(methods)
- Follow-Up Studies
- Humans
- Male
- Neoplasm Grading
- Neoplasm Recurrence, Local
(blood, diagnosis)
- Neoplasm Staging
- Postoperative Complications
- Prognosis
- Prostate-Specific Antigen
(blood)
- Prostatic Neoplasms
(blood, pathology, surgery)
- Retrospective Studies
|